UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comprehensive analysis of immune indicators provides prognostic markers for early stage non-small cell lung cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14276-e14276

2019

Volltextzugriff (PDF)

FLI1 circular RNA as biomarkers for tracking disease progression and as potential therapeutic targets in small cell lung cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e20573-e20573

2018

Volltextzugriff (PDF)

A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13120-e13120

2024

Volltextzugriff (PDF)

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Journal of clinical oncology, 2022-09, Vol.40 (27), p.JCO2102641-3171

2022

Volltextzugriff (PDF)

Effect of MALAT1 in the crosstalk between nucleus and mitochondria on mitochondrial reprogramming in hepatocellular carcinoma cells

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14711-e14711

2019

Volltextzugriff (PDF)

Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20689-e20689

2019

Volltextzugriff (PDF)

Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20083-e20083

2019

Volltextzugriff (PDF)

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16097-e16097

2022

Volltextzugriff (PDF)

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Journal of clinical oncology, 2023-01, Vol.41 (3), p.651-663

2023

Volltextzugriff (PDF)

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2576-2576

2023

Volltextzugriff (PDF)

A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16290-e16290

2023

Volltextzugriff (PDF)

A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8533-8533

2024

Volltextzugriff (PDF)

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9562-9562

2024

Volltextzugriff (PDF)

A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3154-3154

2024

Volltextzugriff (PDF)

A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA -mutated, HR+/HER2- advanced breast cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.1047-1047

2024

Volltextzugriff (PDF)

The correlation between immune status of patients and their prognosis in non-small cell lung cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e23192-e23192

2017

Volltextzugriff (PDF)

Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR -mutant non–small cell lung cancer (NSCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9116-9116

2022

Volltextzugriff (PDF)

Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e18502-e18502

2019

Volltextzugriff (PDF)

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA1013-LBA1013

2023

Volltextzugriff (PDF)

Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2536-2536

2023

Volltextzugriff (PDF)

A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3547-3547

2023

Volltextzugriff (PDF)

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9081-9081

2023

Volltextzugriff (PDF)

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3593-3593

2024

Volltextzugriff (PDF)

Amivantamab plus lazertinib in atypical EGFR -mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8516-8516

2024

Volltextzugriff (PDF)

A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3582-3582

2022

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Aktive Filter

SpracheChinesisch

Zeitschrift / SerieJournal Of Clinical Oncology

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(48)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Comprehensive analysis of immune indicators provides prognostic markers for early stage non-small cell lung cancer

FLI1 circular RNA as biomarkers for tracking disease progression and as potential therapeutic targets in small cell lung cancer

A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Effect of MALAT1 in the crosstalk between nucleus and mitochondria on mitochondrial reprogramming in hepatocellular carcinoma cells

Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer

Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study

A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma

A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study

A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors

A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA -mutated, HR+/HER2- advanced breast cancer

The correlation between immune status of patients and their prognosis in non-small cell lung cancer

Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR -mutant non–small cell lung cancer (NSCLC)

Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)

Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors

A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study

Amivantamab plus lazertinib in atypical EGFR -mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2

A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer

Aktive Filter

Suchergebnisse filtern